Study Protocol Writing at the Celesta Healthcare clinical research centre
Medical Writing · Study Protocols

Study Protocol Writing

The protocol is the document every other study document answers to. We develop BA/BE and clinical trial protocols to ICH E6 (R3) — scientifically sound, operationally feasible, and written for the agency that will review them.

E6 (R3)
ICH-GCP
Aligned
Phase I–IV
Trial Phases
Covered
DCGI · FDA
Agency-Tailored
Protocols
70+
Years Cumulative
Team Experience
Get a Proposal
All Medical Writing
Overview

The Protocol Decides How the Study Goes

A clinical trial protocol defines everything before the first participant is screened: objectives and endpoints, study design, who can enrol, how treatments are given, how safety is monitored, and how the results will be analysed. ICH E6 (R3) — the current good clinical practice guideline — asks for protocols that are clear, concise, scientifically sound, and operationally feasible.

Weak protocols are expensive in slow motion. Eligibility criteria that strangle recruitment, endpoints a statistician cannot cleanly analyse, or visit schedules sites cannot deliver all surface later as amendments, deviations, and delays — each one consuming ethics and regulatory review cycles that a stronger first draft would have avoided.

We write BA/BE study protocols and patient-based clinical trial protocols across Phase I–IV, with biostatisticians shaping the design from the first discussion rather than reviewing it at the end. The writing team works beside a division running 150+ projects, so operational feasibility is judged by people who run studies — not assumed.

Protocol Components

What a Strong Protocol Nails Down

The elements reviewers, ethics committees, and site teams look at first — written so each one survives contact with a real study.

Objectives & Endpoints

Primary and secondary objectives paired with endpoints that are measurable, analysable, and worth measuring.

Eligibility Criteria

Inclusion and exclusion criteria that define the right population without making recruitment impossible.

Design, Randomization & Blinding

Crossover, parallel, or adaptive designs with randomization and blinding procedures matched to the question.

Safety Monitoring & Reporting

Adverse event definitions, stopping rules, and reporting workflows that protect participants and the data.

Statistical Framework

Sample size justification, analysis populations, and hypotheses aligned with the statistical analysis plan.

Amendments & Version Control

Controlled amendment drafting and resubmission support when the study needs to change mid-flight.

Scientific Backbone

Written Next to the People Who Run the Study

A protocol drafted in isolation reads well and runs badly. Ours are written inside a working clinical research division — the same organisation that has executed 65+ studies and currently runs 150+ projects at a DCGI-mandated facility. Clinical operations checks feasibility, pharmacokinetics checks the sampling logic, and biostatistics signs off the design before any sponsor sees a draft.

65+
Studies Executed
150+
Projects Under Execution
E6 (R3)
ICH-GCP Standard
70+
Years Team Experience
How It Runs

Protocol Development Process

  1. 01

    Concept & Feasibility

    Objectives, design options, and the regulatory pathway mapped with clinical, statistical, and regulatory input.

  2. 02

    Synopsis Sign-Off

    A concise synopsis agreed with your team before full drafting — so major revisions happen where they are cheap.

  3. 03

    Full Protocol Draft

    The complete ICH E6 (R3)-aligned protocol: endpoints, eligibility, procedures, safety, and statistics in reviewable form.

  4. 04

    Cross-Functional Review

    Internal review by operations, PK, and biostatistics, then consolidated sponsor comments — version-controlled throughout.

  5. 05

    Final Protocol & Amendments

    An ethics- and agency-ready final version, with controlled amendment support through the life of the study.

Why Celesta

Why Sponsors Choose Us for Protocol Writing

  • Protocols drafted by writers embedded with study operations
  • Statistical design input from in-house biostatisticians, not an afterthought
  • ICH E6 (R3) alignment tailored to DCGI, FDA, and EMA expectations
  • BA/BE, patient trial, and device study protocols under one team
  • Feasibility judged against 150+ live projects, not templates
  • Controlled amendment support through the life of the study
FAQs

Protocol Writing — Frequently Asked Questions

1. What is included in a clinical trial protocol?
A protocol includes the study background and rationale, objectives and endpoints, the trial design, participant inclusion and exclusion criteria, treatment plans and dosing, the visit and assessment schedule, safety monitoring and adverse event reporting procedures, statistical considerations including sample size, and the ethical and administrative framework — consent, data handling, and responsibilities.
2. What is ICH E6 (R3)?
ICH E6 (R3) is the current international good clinical practice guideline, adopted in January 2025. It restructures GCP into overarching principles plus an annex covering ethics committee, investigator, and sponsor responsibilities, and asks for protocols that are clear, concise, and operationally feasible. It also brings a risk-proportionate approach that accommodates decentralised elements and modern data sources.
3. Who writes the clinical trial protocol?
The sponsor is responsible for the protocol, but the writing is typically done by professional medical writers working with clinicians, pharmacokineticists, and biostatisticians — often through a CRO. What matters is that the authors understand both the science and the operational reality of running the study; a protocol is a working instruction manual, not just a scientific document.
4. What is a protocol amendment?
A protocol amendment is a formal, documented change to an approved protocol — for example a revised eligibility criterion, dose change, or added assessment. Substantial amendments must be approved by the ethics committee, and where applicable the regulator, before implementation. Well-managed amendments are version-controlled with a clear rationale so the study record stays clean.
5. How is a BA/BE protocol different from a patient trial protocol?
A BA/BE protocol typically describes a crossover study in healthy adult volunteers with pharmacokinetic endpoints — Cmax and AUC — plus washout periods, timed blood sampling, and bioanalytical method details. A patient trial protocol enrols participants with the target condition and is built around clinical efficacy and safety endpoints, longer treatment durations, and multi-site operations. We write both.
6. How long does protocol development take?
For a well-defined study, expect a synopsis within days of the kickoff discussion and a full reviewable draft within a few weeks — the true variable is decision speed on design questions. Agreeing the synopsis first keeps total time short, because structural changes happen before the full document exists. Timelines are committed per protocol in the proposal.

More Medical Writing Services

Every study type under one roof — explore the rest of our medical writing capabilities.

Medical Writing Overview

CSR Writing

Full and abbreviated clinical study reports in ICH E3 format, written by people who sit beside the study teams.

Learn More

Discuss Your Protocol Writing Requirement

Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.

Get a ProposalContact Us

Need something? Chat with us!